Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.
about
Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association studyIs there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yesCIViC databaseEpidemiology of Lung Cancer in Korea: Recent TrendsEffect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patientsERCC1 and XRCC1 as biomarkers for lung and head and neck cancerA phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial.Myelosuppression induced by concurrent chemoradiotherapy as a prognostic factor for patients with locally advanced non-small cell lung cancerEast meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians.Treatment options for small cell lung cancer - do we have more choice?Inherited variation in the ATP-binding cassette transporter ABCB1 and survival after chemotherapy for stage III-IV lung cancerCommon arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology GReduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis.The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivityPredictive value of XPD polymorphisms on platinum-based chemotherapy in non-small cell lung cancer: a systematic review and meta-analysis.Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: a meta-analysis of 24 studies.Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual.Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis.A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.Comparing lung cancer risks in sweden, USA, and Japan.Guideline-Based Peer-to-Peer Consultation Optimizes Pegfilgrastim Use With No Adverse Clinical Consequences.Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer.Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: an east asian population-based studyIncidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study.The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncologyEfficacy and toxicity of salvage weekly paclitaxel chemotherapy in non-Asian patients with advanced oesophagogastric adenocarcinoma.Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han populationIncidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy.CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis.Bevacizumab in non-small-cell lung cancer: a review.An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs.Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials.Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy.Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the 'common arm' approach.Germline pharmacogenetics of paclitaxel for cancer treatment.
P2860
Q21261276-0B4C7619-8114-4BEC-A2D8-970D32D54D0BQ26766180-C5DBD7FE-FA81-48F9-9391-87787E223E14Q27612411-8EDC4136-F4DD-4BA2-B17F-B4BEF34F7476Q28077423-30CBB4D6-4DBC-4DB4-8770-79737AC6FB29Q28382908-E025A82D-1660-4AFF-8DF9-5F0B568DD6E2Q28391646-800264E8-CAB2-475D-A5ED-7EDE30B2590AQ33166212-4AC17D18-ABC5-4486-87E1-6674E633BD22Q33402694-7F6E94E0-43CB-40DE-B5A5-6946757A0008Q33579631-0D55D86D-A751-433E-9790-DF39DEF88162Q33723735-81098EFF-EDCC-4692-BB93-041C8381F2ECQ34050097-54264BFD-8231-4042-B4EA-DD868002055DQ34367343-CAAFD0F1-EBE1-4917-948E-CB4833CA9767Q34498728-FA930C13-991D-49CE-8BD3-A8ED96700359Q34630819-8114CA5A-7B89-4F46-8384-54ECA345A919Q34676948-0ADABD86-7B76-48FA-8CBE-BB3294DFA476Q34973738-99FBE24C-0447-4013-8302-F2BCB8983753Q35048754-CC2C0161-B550-49C5-A147-646A1AA36C7DQ35237134-DF073262-9FFF-4A34-A455-B81C64691B73Q35473988-9EF80331-A540-401D-A0D7-CCE10D63228EQ35510634-B4EB2107-CB67-4EE1-8543-E9596E5A9917Q35775244-FB07AD61-7210-48DD-A143-B6E8D165E372Q35864294-D48D6C3F-BCC0-45E5-A182-9D9EF41504E2Q35947740-8F6EB8D4-041F-4E5C-ACB4-A4AD9B109333Q36072056-0724F92C-36BC-43BF-BFEC-C15893B58FDBQ36349601-97758E5F-C269-47C4-80DE-B25652BB44ABQ36406111-B53E950B-4A14-4FA9-83D1-B96DBFCAC53AQ36463971-1AA562D0-DCB0-482C-B8FD-20101F2CF4E6Q36579220-685F13C4-C91E-41E9-93C4-800437222D05Q36681506-74D2E3DF-A06C-4D50-94B7-D0B17F7B205DQ36769011-90ED7BFD-3D5C-4FAE-BD9C-B9A8A1970E3CQ37055326-A69775BA-AC56-473F-B547-D419FA8BC3A1Q37684533-ED59A04C-6D62-45B3-8534-6DDBB7D9D8AEQ37689573-4D824EDB-11B6-4F6E-B442-E94CE436D4F2Q37931886-2EEDDF72-1D4D-4431-85E6-BFA0DA3E7044Q37939200-FD3D4847-E00D-4AE3-8F78-E36884CBB558Q37957744-F410B469-AD43-4881-9359-FD75ADC19B05Q37994654-1C7B1916-D7F8-4889-9642-E6B633E01FD2Q38003669-889B6030-224E-47EE-A83F-D2B5E9495F73Q38068587-0DBBC8CE-C7D2-405E-9088-193DE0E40158Q38120289-EC1B30EA-E107-4894-AA6C-625BB34DAEA7
P2860
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Japanese-US common-arm analysi ...... tion-related pharmacogenomics.
@ast
Japanese-US common-arm analysi ...... tion-related pharmacogenomics.
@en
Japanese-US common-arm analysi ...... tion-related pharmacogenomics.
@nl
type
label
Japanese-US common-arm analysi ...... tion-related pharmacogenomics.
@ast
Japanese-US common-arm analysi ...... tion-related pharmacogenomics.
@en
Japanese-US common-arm analysi ...... tion-related pharmacogenomics.
@nl
altLabel
Japanese-US Common-Arm Analysi ...... ation-Related Pharmacogenomics
@en
prefLabel
Japanese-US common-arm analysi ...... tion-related pharmacogenomics.
@ast
Japanese-US common-arm analysi ...... tion-related pharmacogenomics.
@en
Japanese-US common-arm analysi ...... tion-related pharmacogenomics.
@nl
P2093
P2860
P3181
P356
P1476
Japanese-US common-arm analysi ...... tion-related pharmacogenomics.
@en
P2093
Charles Arthur Coltman
Howard L McLeod
James Moon
John Crowley
Kaoru Kubota
Kiyoyuki Furuse
Masaaki Kawahara
Masahiro Fukuoka
Masanori Fukushima
Nagahiro Saijo
P2860
P304
P3181
P356
10.1200/JCO.2008.20.8793
P407
P577
2009-07-20T00:00:00Z